CELEBRATION, Fla., Aug. 09, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS:KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery, development and commercialization of novel treatments for rare central nervous system (CNS), neurodegenerative and lysosomal storage diseases, today announced the appointment of Nichol Ochsner to the role of Vice President, Investor Relations and Corporate Communications. In this newly created position, Ms. Ochsner will be responsible for driving external awareness of KemPharm’s value proposition, including ongoing relations with the Company’s shareholders, covering analysts and prospective investors.
Read more at globenewswire.comKemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications
Globe Newswire -
Tue Aug 9, 2022
Columnist
Contributor Content
Press Release
Sponsored Content
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
This article could contain syndicated content. We have not reviewed, approved, or endorsed the content and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Intel%20Corp_%20Santa%20Clara%20campus-by%20jejim%20via%20Shutterstock.jpg)
/Chipotle%20Mexican%20Grill%20lunch%20by-%20dennizn%20via%20Shutterstock.jpg)
/Tesla%20Inc%20logo%20by-%20baileystock%20via%20iStock.jpg)
